Business
TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call
TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TS...
About this update from Terrascend Corp.
[{"type":"text","content":"TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference CallFirst Quarter 2026 Net Revenue Totaled $65.5 million with Gross Profit Margin of 52.8%\nTORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (\"TerrAscend\" or the \"Company\") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced preliminary and unaudited financial results for the first quarter ended March 31, 2026. All amounts are in U.S. dollars. The preliminary and unaudited financial results reported herein are from continuing operations, and do not include Michigan, which are reported as discontinued operations effective as of the second quarter ended June 30, 2025. All historical periods have been restated accordingly. For the first quarter of 2026, the Company anticipates: Net Revenue of $65.5 million, compared to $66.1 million in the fourth quarter of 2025 and $64.3 million in the first quarter of 2025.Gross Profit Margin of 52.8%, compared to 52.1% in the fourth quarter of 2025 and 53.9% in the first quarter of 2025.General and Administrative expenses were flat quarter-over-quarter.Generated Positive Cashflow from Operations for the 15th consecutive quarter. “The business returned to year-over-year revenue growth from continuing operations, while gross margin and other key profitability metrics exceeded our targets for the quarter. This positive operational momentum, combined with the recently completed rescheduling of medical cannabis, and the promise of further progress, has the team more excited than ever about the future,” said Jason Wild, Executive Chairman of TerrAscend. “We remain committed to executing on our business strategy, driving efficiency, profitability, and growth while continuing to generate cash flow across our core markets. Together with our strong balance sheet and disciplined approach to capital allocation and M&A, we are positioned to deliver value for patients, customers, and shareholders. I look forward to sharing additional details on our upcoming earnings call.” Conference Call Details:The Company will host a conference call to discuss the results for its first quarter ended March 31, 2026 on Thursday, May 7, 2026 at 8:00 a.m. Eastern Time. The Company will report its financial results for the ...